SunTrust Downgrades Tetraphase Pharmaceuticals (TTPH) to Neutral

Nomura Securities Downgrades Tetraphase Pharmaceuticals (TTPH) to Neutral

Nomura Securities downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Buy to Neutral with a price target of $10.00 (from $54.00).

Analyst M. Ian Somaiya commented, "We are downgrading TTPH to Neutral and cutting our TP to $10 from $54 following the announcement that the IGNITE-2 Phase III... More

Stifel Downgrades Tetraphase Pharmaceuticals (TTPH) to Hold

Stifel downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Buy to Hold.

For an analyst ratings summary and ratings history on Tetraphase Pharmaceuticals click here. For more ratings news on Tetraphase Pharmaceuticals click here.

Shares of Tetraphase Pharmaceuticals closed at $44.78 yesterday.

Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data.

Guggenheim reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ: TTPH), and cut the price target to $20.00 (from $60.00), on disappointing cUTI data.

Analyst Louise Chen commented, "Despite disappointing cUTI data, we are maintaining our BUY rating for TTPH shares, but we are lowering our price target from $60 to $20. The decrease in our PT is driven by downwards earnings revisions and multiple contraction. In... More

Needham & Company Downgrades Tetraphase Pharmaceuticals (TTPH) to Hold

Needham & Company downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Buy to Hold after the company announced negative results from its Phase 3 trial of IV/oral eravacycline in complicated Urinary Tract Infections (cUTI; IGNITE2).

Analyst Alan Carr commented, "We had expected a favorable outcome... More

Brean Capital Downgrades Tetraphase Pharmaceuticals (TTPH) to Hold

Brean Capital downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Buy to Hold until a clearer path forward emerges.

Analyst Jonathan Aschoff commented, "Tetraphase announced yesterday that its pivotal Phase 3 IGNITE2 trial with antibiotic eravacycline administered as an IV to oral transition therapy failed to achieve... More

Baird Downgrades Tetraphase Pharmaceuticals (TTPH) to Neutral

Baird downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Outperform to Neutral with a price target of $10.00 (from $41.00).

Analyst Brian Skorney commented, "The failure of IGNITE2, one of the company's two Phase 3 studies, leaves eravacycline's future very much in jeopardy. Even if there is a path to... More

Wedbush Downgrades Tetraphase Pharmaceuticals (TTPH) to Neutral

Wedbush downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Outperform to Neutral with a price target of $11.00 after Eravacyline failed to demonstrate non-inferiority to levofloxacin in its IV to oral stepdown study in complicated urinary tract infections for the FDA or EMA endpoints despite superiority in quinolone resistant pathogens.

The analyst notes details were lacking on reason for failure at this time. "We believe some possibilities for the... More

UPDATE: Cantor Fitzgerald Downgrades Tetraphase Pharmaceuticals (TTPH) to Hold

(Updated - September 9, 2015 7:14 AM EDT)

Cantor Fitzgerald downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Buy to Hold after the company announced the phase 3 IGNITE2 failed to meet the pre-specified 10% non-inferiority margin in both the FDA and EMA approvable clinical endpoints.

Analyst Daniel Brims... More

Tetraphase Pharma's (TTPH) IGNITE2 Phase 3 Missed Primary Endpoint in cUTI

Tetraphase Pharma (NASDAQ: TTPH) announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not achieve its primary endpoint of statistical non-inferiority compared to levofloxacin.

"We are disappointed that the IGNITE2 trial did not achieve its primary endpoint. We plan to further analyze the data and provide an update after we have discussed the data and our plans for a path forward with the regulatory agencies," said Guy Macdonald, President and CEO of Tetraphase. "We previously... More